IRTC
NEUTRAL
$115.24
Live
iRhythm Holdings, Inc. · NASDAQ
Target $201.71
(+75.0%)
$97.16
52W Range
$212.0
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 12, 2026
Market cap
$3.72B
P/E
N/A
ROE
-36.6%
Profit margin
-6.0%
Debt/Equity
4.79
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
80%
IRTC presents a stark contrast between fundamental health and growth potential, anchored by a weak Piotroski F-Score of 2/9. While the company demonstrates strong top-line revenue growth (27.1%) and impressive gross margins (70.57%), it is burdened by a high Debt/Equity ratio of 4.79 and a prohibitively expensive Forward P/E of 137.79. Recent earnings beats and a shift toward positive EPS provide a bullish catalyst, but these are offset by bearish insider activity and a complete lack of technical momentum. The stock is currently a speculative growth play rather than a value investment.
Key Strengths
Strong revenue growth of 27.10% YoY
High gross margins at 70.57%
Recent trend of beating earnings estimates (3/4 last quarters)
Strong short-term liquidity with a Current Ratio of 4.63
Strong analyst consensus (Strong Buy) with a high target price of $201.71
Key Risks
Critically low Piotroski F-Score (2/9) indicating poor financial health
Extreme valuation with a Forward P/E of 137.79 and Price/Book of 24.37
High leverage with a Debt/Equity ratio of 4.79
Consistent insider selling ($12.07M) with zero insider buying
Negative overall profit margin (-5.96%) and ROE (-36.57%)
AI Fair Value Estimate
Based on comprehensive analysis
$132.5
+15.0% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
30
Weak
15
75
40
20
0
AI Verdict
Speculative Growth
Key drivers: Revenue expansion, EPS recovery, Extreme valuation premium, Poor balance sheet health
Confidence
85%
Value
15/100
No Graham Number available; valuation is driven by future growth expectations rather than current assets or earnings.
Positives
- Price/Sales is moderate at 4.98
Watchpoints
- Forward P/E of 137.79 is unsustainable
- Price/Book of 24.37 indicates massive premium over assets
Future
75/100
Growth rates are strong, and the company is trending toward consistent profitability.
Positives
- 27% YoY revenue growth
- Recent positive EPS surprise (+1587.3% in Feb 2026)
Watchpoints
- High dependency on continued rapid growth to justify valuation
Past
40/100
Historical performance shows a company struggling to reach profitability despite scaling revenue.
Positives
- Consistent history of beating estimates in recent quarters
Watchpoints
- Long-term history of negative earnings
- Recent 6-month price decline of 34.6%
Health
20/100
Deterministic health scores indicate severe fundamental weakness despite high liquidity.
Positives
- High Current Ratio (4.63) suggests no immediate liquidity crisis
Watchpoints
- Piotroski F-Score of 2/9 is a major red flag
- Debt/Equity of 4.79 is significantly high
Dividend
0/100
Company is in a growth phase and does not return capital to shareholders.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0% payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$115.24
Analyst Target
$201.71
Upside/Downside
+75.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for IRTC and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
IRTC
iRhythm Holdings, Inc.
Primary
|
+43.4% | -13.2% | +16.6% | -34.6% | -3.7% | -1.3% |
|
AMRX
Amneal Pharmaceuticals, Inc.
Peer
|
+69.5% | +727.3% | +34.6% | +18.3% | -19.5% | -10.7% |
|
INDV
Indivior Pharmaceuticals, Inc.
Peer
|
+218.1% | +75.0% | +241.6% | +28.4% | -7.0% | +0.2% |
|
ADMA
ADMA Biologics, Inc.
Peer
|
+604.6% | +370.5% | -15.4% | -6.0% | -6.9% | -1.6% |
|
ALHC
Alignment Healthcare, Inc.
Peer
|
+11.0% | +93.4% | +42.7% | +17.5% | -12.9% | -6.7% |
IRT
iRhythm Holdings, Inc.
Primary
5Y
+43.4%
3Y
-13.2%
1Y
+16.6%
6M
-34.6%
1M
-3.7%
1W
-1.3%
AMR
Amneal Pharmaceuticals, Inc.
Peer
5Y
+69.5%
3Y
+727.3%
1Y
+34.6%
6M
+18.3%
1M
-19.5%
1W
-10.7%
IND
Indivior Pharmaceuticals, Inc.
Peer
5Y
+218.1%
3Y
+75.0%
1Y
+241.6%
6M
+28.4%
1M
-7.0%
1W
+0.2%
ADM
ADMA Biologics, Inc.
Peer
5Y
+604.6%
3Y
+370.5%
1Y
-15.4%
6M
-6.0%
1M
-6.9%
1W
-1.6%
ALH
Alignment Healthcare, Inc.
Peer
5Y
+11.0%
3Y
+93.4%
1Y
+42.7%
6M
+17.5%
1M
-12.9%
1W
-6.7%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
137.79
PEG Ratio
N/A
P/B Ratio
24.37
P/S Ratio
4.98
EV/Revenue
5.18
EV/EBITDA
-126.66
Market Cap
$3.72B
Profitability
Profit margins and return metrics
Profit Margin
-5.96%
Operating Margin
4.2%
Gross Margin
70.57%
ROE
-36.57%
ROA
-2.36%
Growth
Revenue and earnings growth rates
Revenue Growth
+27.1%
Earnings Growth
N/A
Q/Q Revenue Growth
+27.12%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
4.79
High debt
Current Ratio
4.63
Strong
Quick Ratio
4.34
Excellent
Cash/Share
$18.06
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.2B
Gross Margin
70.9%
Op. Margin
2.4%
Net Margin
2.7%
Total Assets
$1.0B
Liabilities
$0.9B
Equity
$0.2B
Debt/Equity
5.68x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
55%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-30
$N/A
2026-02-19
$0.17
+1587.3% surprise
2025-10-30
$-0.06
+78.8% surprise
2025-07-31
$-0.32
+32.5% surprise
Healthcare Sector Comparison
Comparing IRTC against 264 companies in the Healthcare sector
(20 bullish, 87 neutral, 157 bearish)
Return on Equity (ROE)
-36.57%
This Stock
vs
-46.09%
Sector Avg
-20.7%
(Below Avg)
Profit Margin
-5.96%
This Stock
vs
-19.58%
Sector Avg
-69.6%
(Weaker)
Debt to Equity
4.79
This Stock
vs
4.1
Sector Avg
+16.8%
(Higher)
Revenue Growth
27.1%
This Stock
vs
88.16%
Sector Avg
-69.3%
(Slower)
Current Ratio
4.63
This Stock
vs
3.58
Sector Avg
+29.3%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
IRTC
iRhythm Holdings, Inc.
|
NEUTRAL | $3.72B | - | -36.6% | -6.0% | $115.24 | |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
BEARISH | $3.72B | 53.77 | -% | 2.4% | $11.83 | Compare |
|
INDV
Indivior Pharmaceuticals, Inc.
|
NEUTRAL | $3.82B | 18.62 | -% | 16.9% | $30.54 | Compare |
|
ADMA
ADMA Biologics, Inc.
|
BEARISH | $3.61B | 25.25 | 35.6% | 28.8% | $15.15 | Compare |
|
ALHC
Alignment Healthcare, Inc.
|
BEARISH | $3.85B | - | -0.7% | -0.0% | $19.22 | Compare |
IRTC
iRhythm Holdings, Inc.
NEUTRAL
Mkt Cap
$3.7B
P/E
-
ROE
-36.6%
Price
$115.24
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-16 | SMITH MERVIN | Officer | Sale | 2,585 | $295,466 |
| 2026-03-02 | BLACKFORD QUENTIN S | Chief Executive Officer | Sale | 13,813 | $1,774,174 |
| 2026-03-02 | MURPHY PATRICK MICHAEL | Chairman of the Board | Sale | 4,357 | $559,624 |
| 2026-03-02 | PATTERSON CHAD | Officer | Sale | 4,444 | $570,804 |
| 2026-03-02 | SHRISHRIMAL SUMI | Officer | Sale | 2,830 | $363,484 |
| 2026-03-02 | WILSON DANIEL G | Chief Financial Officer | Sale | 3,395 | $436,076 |
| 2026-03-02 | TURAKHIA MINANG | Officer | Sale | 4,027 | $517,259 |
| 2026-03-02 | ROSENBAUM MARK W | Officer | Sale | 816 | $104,815 |
| 2026-03-02 | SMITH MERVIN | Officer | Sale | 1,352 | $173,652 |
| 2026-02-25 | LAWRENCE BRIAN LEE | Chief Technology Officer | Stock Award | 6,689 | - |
| 2026-02-25 | BLACKFORD QUENTIN S | Chief Executive Officer | Sale | 25,540 | $3,458,599 |
| 2026-02-25 | BLACKFORD QUENTIN S | Chief Executive Officer | Stock Award | 31,842 | - |
| 2026-02-25 | MURPHY PATRICK MICHAEL | Officer | Sale | 7,805 | $1,056,945 |
| 2026-02-25 | MURPHY PATRICK MICHAEL | Chairman of the Board | Stock Award | 7,024 | - |
| 2026-02-25 | PATTERSON CHAD | Officer | Sale | 8,967 | $1,214,301 |
SMITH MERVIN
Officer
2026-03-16
2,585 shares
·
$295,466
BLACKFORD QUENTIN S
Chief Executive Officer
2026-03-02
13,813 shares
·
$1,774,174
MURPHY PATRICK MICHAEL
Chairman of the Board
2026-03-02
4,357 shares
·
$559,624
PATTERSON CHAD
Officer
2026-03-02
4,444 shares
·
$570,804
SHRISHRIMAL SUMI
Officer
2026-03-02
2,830 shares
·
$363,484
WILSON DANIEL G
Chief Financial Officer
2026-03-02
3,395 shares
·
$436,076
TURAKHIA MINANG
Officer
2026-03-02
4,027 shares
·
$517,259
ROSENBAUM MARK W
Officer
2026-03-02
816 shares
·
$104,815
SMITH MERVIN
Officer
2026-03-02
1,352 shares
·
$173,652
LAWRENCE BRIAN LEE
Chief Technology Officer
2026-02-25
6,689 shares
BLACKFORD QUENTIN S
Chief Executive Officer
2026-02-25
25,540 shares
·
$3,458,599
BLACKFORD QUENTIN S
Chief Executive Officer
2026-02-25
31,842 shares
MURPHY PATRICK MICHAEL
Officer
2026-02-25
7,805 shares
·
$1,056,945
MURPHY PATRICK MICHAEL
Chairman of the Board
2026-02-25
7,024 shares
PATTERSON CHAD
Officer
2026-02-25
8,967 shares
·
$1,214,301
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
14 analysts
Goldman Sachs
2026-04-09
Neutral
Neutral
Evercore ISI Group
2026-04-06
Outperform
Outperform
Citigroup
2026-03-11
Buy
Buy
Truist Securities
2026-02-23
Buy
Buy
Canaccord Genuity
2026-02-20
Buy
Buy
JP Morgan
2026-02-20
Overweight
Overweight
Wells Fargo
2026-02-20
Overweight
Overweight
Baird
2026-02-20
Outperform
Outperform
Wells Fargo
2026-01-13
Overweight
Overweight
Needham
2026-01-12
Buy
Buy
Past News Coverage
Recent headlines mentioning IRTC from our newsroom.
Newest → oldest
No matching news yet.